Andra AP-fonden’s Vertex Pharmaceuticals VRTX Stock Holding History

Andra AP-fonden’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.7M	Sell	23,903 -12,037	-33%	-$5.61M	0.13%	193
2025 Q4	$16.3M	Buy	35,940 +40	+0.1%	+$17.2K	0.2%	151
2025 Q3	$14.1M	Buy	+35,900	New	+$15M	0.18%	175
2025 Q2	–	Sell	-5,500	Closed	-$2.67M	–	510
2025 Q1	$2.67M	Sell	5,500 -30,600	-85%	-$14.3M	0.04%	334
2024 Q4	$14.5M	Sell	36,100 -5,500	-13%	-$2.55M	0.23%	170
2024 Q3	$19.3M	Sell	41,600 -28,200	-40%	-$13.5M	0.28%	121
2024 Q2	$32.7M	Sell	69,800 -12,000	-15%	-$5.21M	0.55%	40
2024 Q1	$34.2M	Buy	81,800 +58,800	+256%	+$24.9M	0.61%	34
2023 Q4	$9.36M	Buy	23,000 +5,800	+34%	+$2.14M	0.5%	72
2023 Q3	$5.98M	Sell	17,200 -800	-4%	-$280K	0.35%	131
2023 Q2	$6.33M	Sell	18,000 -16,600	-48%	-$5.59M	0.16%	299
2023 Q1	$10.9M	Sell	34,600 -9,400	-21%	-$2.82M	0.28%	84
2022 Q4	$12.7M	Sell	44,000 -13,000	-23%	-$3.96M	0.39%	24
2022 Q3	$16.5M	Sell	57,000 -6,100	-10%	-$1.76M	0.54%	5
2022 Q2	$17.8M	Buy	+63,100	New	+$16.9M	0.51%	2
2021 Q4	$16.6M	Buy	75,600 +4,100	+6%	+$797K	0.34%	43
2021 Q3	$13M	Buy	71,500 +2,700	+4%	+$527K	0.27%	88
2021 Q2	$13.9M	Buy	68,800 +22,500	+49%	+$4.71M	0.28%	68
2021 Q1	$9.95M	Sell	46,300 -5,000	-10%	-$1.1M	0.22%	170
2020 Q4	$12.1M	Buy	51,300 +20,800	+68%	+$4.77M	0.27%	69
2020 Q3	$8.3M	Buy	30,500 +200	+0.7%	+$55.2K	0.23%	119
2020 Q2	$8.8M	Buy	30,300 +6,200	+26%	+$1.68M	0.26%	46
2020 Q1	$5.74M	Buy	24,100 +1,600	+7%	+$367K	0.21%	109
2019 Q4	$4.93M	Buy	22,500 +4,300	+24%	+$870K	0.14%	388
2019 Q3	$3.08M	Hold	18,200	–	–	0.09%	535
2019 Q2	$3.34M	Sell	18,200 -10,700	-37%	-$1.87M	0.1%	534
2019 Q1	$5.32M	Buy	+28,900	New	+$5.34M	0.15%	332
2018 Q3	$7M	Buy	36,300 +2,000	+6%	+$356K	0.18%	215
2018 Q2	$5.83M	Sell	34,300 -4,700	-12%	-$729K	0.16%	300
2018 Q1	$6.36M	Buy	39,000 +16,200	+71%	+$2.65M	0.16%	272
2017 Q4	$3.42M	Buy	22,800 +900	+4%	+$133K	0.08%	399
2017 Q3	$3.33M	Buy	21,900 +12,300	+128%	+$1.85M	0.08%	401
2017 Q2	$1.24M	Buy	+9,600	New	+$1.16M	0.03%	608
2017 Q1	–	Sell	-3,400	Closed	-$250K	–	651
2016 Q4	$250K	Sell	3,400 -4,600	-58%	-$374K	0.01%	641
2016 Q3	$698K	Sell	8,000 -4,600	-37%	-$435K	0.02%	578
2016 Q2	$1.08M	Buy	12,600 +4,900	+64%	+$423K	0.03%	617
2016 Q1	$612K	Buy	7,700 +2,100	+38%	+$190K	0.02%	647
2015 Q4	$705K	Sell	5,600 -1,500	-21%	-$181K	0.02%	576
2015 Q3	$739K	Hold	7,100	–	–	0.02%	582
2015 Q2	$877K	Sell	7,100 -1,700	-19%	-$214K	0.03%	573
2015 Q1	$1.04M	Sell	8,800 -6,700	-43%	-$803K	0.03%	555
2014 Q4	$1.84M	Sell	15,500 -100	-0.6%	-$11.3K	0.04%	487
2014 Q3	$1.75M	Buy	+15,600	New	+$1.49M	0.04%	454
2014 Q2	–	Sell	-30,900	Closed	-$2.19M	–	575
2014 Q1	$2.19M	Sell	30,900 -1,400	-4%	-$111K	0.05%	419
2013 Q4	$2.4M	Sell	32,300 -3,100	-9%	-$216K	0.06%	410
2013 Q3	$2.68M	Buy	35,400 +8,300	+31%	+$660K	0.07%	384
2013 Q2	$2.16M	Buy	+27,100	New	+$2M	0.06%	413

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Andra AP-fonden's VRTX Position: Q1 2026 in Review

Andra AP-fonden reduced its Vertex Pharmaceuticals (VRTX) stake by 33% in Q1 2026, selling an estimated $5.61M and leaving 23,903 shares worth $10.7M. The position accounts for 0.13% of the portfolio, ranked #193.

Andra AP-fonden first reported a position in VRTX in Q2 2013 and has held it in 47 quarters since. The position peaked at $34.2M in Q1 2024. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Andra AP-fonden held 23,903 shares of Vertex Pharmaceuticals worth $10.7M as of Q1 2026.
Andra AP-fonden sold 12,037 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.61M.
Vertex Pharmaceuticals made up 0.13% of Andra AP-fonden's portfolio in Q1 2026, its #193 holding.
Andra AP-fonden first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
Andra AP-fonden's Vertex Pharmaceuticals position peaked at $34.2M in Q1 2024.
1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Andra AP-fonden's 13F filing for Q1 2026, filed 8 May 2026.